Merck (MRK) will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively. Earnings estimates for Merck have declined from $8.01 to $7.80 per share over the past 30 days. For 2025, earnings estimates have declined from $9.70 to $9.64 per share over the same timeframe.Image Source: Zacks Investment ResearchEarnings Surprise History of MerckThe healthcare bellwether’s performance has been ...

Merck (MRK) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 31. On ...

Merck's (MRK) stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 Index, as seen in the chart below. The stock is also trading below its 200- and 50-day moving averages. Merck Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key t ...

Gilead Sciences, Inc. (GILD) and partner Merck (MRK) announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed a treatment switch to an investigational oral once-weekly combination regimen of islatravir and lenacapavir maintained viral suppression in adults at week 48.Shares of the company have risen 6.2% year to date against the industry’s decline of 1.7%.Image Source: Zacks Investment ResearchData From GILD an ...

The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021.Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step closer to filing for approval of the shot. The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV, which causes thousands of deaths among older Americans and hundreds of deaths amo ...

Merck (MRK) closed at $111.53 in the latest trading session, marking a +1.68% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.Coming into today, shares of the pharmaceutical company had lost 7.01% in the past month. In that same time, the Medical sector lost 3.35%, while the S&P 500 gained 4.31%.The upcoming earnings release of Merck will be of great interest to investors. The company's earning ...

文章核心观点 - 大型制药公司Pfizer和Merck目前股价较低,存在投资机会 [1][2][5] - Pfizer正在实施成本削减计划,未来有望通过新药上市和资本回报提振股价 [3][4] - Merck面临Keytruda专利到期的不确定性,但持续的研发投入有望弥补收入缺口 [5][6][7][8] Pfizer - Pfizer 2022年从新冠疫苗和药物销售中获得超过100亿美元收入,但近期业绩下滑 [2] - Pfizer正在实施成本削减计划,预计到2028年可节省15亿美元,并将加大内部研发投入和资本回报 [3] - Pfizer新收购的肿瘤药业务有望在未来带来增长动力 [4] Merck - Merck近期也出现了几个季度的亏损,但有超过30个三期临床项目 [5] - Merck的重磅产品Keytruda专利将于2028年到期,存在收入不确定性 [5] - Merck正大幅投资研发,并通过收购生物科技公司获取新的临床阶段资产 [6][8]

Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Activated Polyethylene Glycol Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global activated polyethylene glycol market is expected to reach an estimated $162 million by 2030 with a CAGR of 2.4% from 2024 to 2030. The major drivers for this market are the chemical and pharmaceutical sectors are expanding quickly, rapid advancement in molecular biology and biotechnology, as well ...

文章核心观点 - 全球香料市场规模在2023年达到了13亿美元,预计到2032年将增长到21亿美元,复合年增长率为5.5% [1][8] - 香料是一种天然多酚化合物,具有抗衰老、抗水肿、抗氧化和抗炎症等特性,广泛应用于功能性食品、膳食补充剂、医药和化妆品 [2] 行业趋势 - 全球食品饮料行业的快速增长是推动市场增长的关键因素,香料广泛用作着色剂和添加剂 [3] - 消费者对优质化妆品和护肤品的偏好上升,香料被添加到这些产品中以保护和修复皮肤受污染、紫外线和阳光的损害 [4] - 消费者支出能力的提高以及研发活动的增加也将推动市场增长 [4] 竞争格局 - 行业竞争格局包括Alchem International、Bordas、Cayman Chemical Company等主要企业 [5][6]

文章核心观点 - 默克公司(Merck)自夏季初以来一直在下跌,尤其是在公司下调全年利润预期后 [1] - 默克公司股价下跌的主要原因是公司下调了全年利润预期 [1] 公司概况 - 默克公司是一家制药公司,总部位于美国 [1] - 默克公司股票代码为MRK,在纽约证券交易所上市 [1] 公司业绩 - 默克公司近几年业绩表现良好,一直在超越大盘 [1] - 但最近几周默克公司股价持续下跌 [1] 分析师评论 - 分析师表示自己持有默克公司股票的多头头寸 [2] - 分析师表示自己撰写了这篇文章,文章表达的是自己的观点 [2] - 分析师表示没有从任何公司获得报酬 [2] 免责声明 - 寻求阿尔法网站表示过去的业绩不能保证未来的结果 [2] - 寻求阿尔法网站表示不会就任何投资的适合性提供建议或意见 [2] - 寻求阿尔法网站表示其分析师是第三方作者,可能不是持牌的证券交易商、经纪人或投资顾问 [2]